PT  - JOURNAL ARTICLE
AU  - Richardson, Ciaran
AU  - Gildea, Sarah
AU  - Harkin, Stephen
AU  - Gallagher, Annie
AU  - Conroy, Eimear
AU  - McClafferty, Lorraine
AU  - McCole, Eibhlin
AU  - Benchikh, El Ouard
AU  - Reid, Cherith N.
AU  - Dunlop, Marshall
AU  - Savage, Sharon
AU  - Lowry, Philip
AU  - Curry, Jim
AU  - McConnell, Robert I.
AU  - Lamont, John V.
AU  - FitzGerald, Stephen P.
TI  - Development of a rapid SARS-CoV-2 neutralisation test by detecting antibodies that block interaction of spike protein receptor-binding domain (RBD) with angiotensin-converting enzyme 2 (ACE2)
AID  - 10.1101/2021.06.03.21255116
DP  - 2021 Jan 01
TA  - medRxiv
PG  - 2021.06.03.21255116
4099  - http://medrxiv.org/content/early/2021/06/03/2021.06.03.21255116.short
4100  - http://medrxiv.org/content/early/2021/06/03/2021.06.03.21255116.full
AB  - The urgent need for a rapid and reliable Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) neutralising antibody detection test compatible with routine clinical laboratory testing currently exists. This is necessary to provide accurate estimates of immunity and to monitor vaccine effectiveness. Utilising Biochip Array Technology (BAT), the Randox SARS-CoV-2 Biochip proxy virus neutralisation test (pVNT) has been developed. Immobilising SARS-CoV-2 Spike RBD on the Biochip surface, innovative assay design enables direct sample addition to the Biochip well without the need for off-board sample pre-incubation step. Results are reported within 1.5 hours and testing is carried out without the prerequisite of live virus or biosafety level 3 (BSL3) laboratory facilities. In this study, assay validation is performed using recombinant antibodies and clinical samples and an excellent correlation against conventional virus neutralisation methods is established (100% clinical specificity and 98% clinical sensitivity). Serial dilution of samples with high neutralising antibody levels demonstrate end-point sample dilutions comparable with those obtained using the SARS-CoV-2 microneutralisation test. Species independent neutralising antibody detection capacity of the SARS-CoV-2 Biochip pVNT is also demonstrated. The findings of this study exemplify the utility of the SARS-CoV-2 Biochip pVNT as a robust and reliable method for the accurate measurement of neutralising antibodies against SARS-CoV-2 and the availability of this test can now positively impact current testing deficiencies in this area.Competing Interest StatementCR,SG, SH, AG, EC, LM, EM, EOB, CNR, MD, SS, PL, JC, RIM, JVL, SPF are employees of Randox. SPF is the owner of Randox.Funding StatementNo external funding was received.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Informed consent has been obtained for all clinical samples utilised in this study. In addition, formal guidance regarding ethical requirements has been sought from the Head of the Office for Research Ethics Committees Northern Ireland (ORECNI) who confirmed that under the Human Tissue Act Code of Practice and Standards for Research, clinical samples used in this manuscript are not classified as relevant material and therefore ethical approval is not required. Immunisation and the collection of samples from sheep was carried out under Animals (Scientific Procedures) Act 1986 Project License number PPL2797.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe data that support the findings of this study are available from the corresponding author, CR, upon reasonable request.